BACKGROUNDNausea and vomiting are distressing symptoms reported by pediatric oncology patients during cancer treatment. More than 40% of them experience these symptoms even after receiving antiemetics.OBJECTIVEGiven the limitations of pharmacological interventions, this systematic review synthesized the evidence for the effectiveness of complementary and alternative medicine in controlling nausea and vomiting among pediatric oncology patients.METHODSTen databases were searched to identify relevant randomized controlled trials. The risk of bias of selected studies was graded using the Cochrane risk-of-bias tool for randomized trials. The primary outcomes were nausea and vomiting. The secondary outcomes were intervention adherence and number of adverse events.RESULTSNineteen papers met the inclusion criteria and were included in the review. Sixteen studies showed high risk of bias. The tested interventions were acupuncture, acupressure, aromatherapy, hypnosis, massage, active cognitive distraction/relaxation techniques, creative arts therapy, psychoeducation, and combined massage and acupressure. Acupuncture, hypnosis, and massage interventions improved nausea and vomiting. Fifteen trials reported intervention adherence; only 7 monitored adverse events. The most common reason for dropout was refusal from patients and/or their guardians. A total of 34 adverse events were noted.CONCLUSIONSThere is insufficient evidence that complementary and alternative medicine is effective, feasible, or safe in controlling nausea and vomiting among pediatric oncology patients due to high risk of bias.IMPLICATIONS FOR PRACTICEAcupuncture, hypnosis, and massage appear to have therapeutic benefits. However, more robust studies are needed to address the identified methodological issues and determine the real value of these 3 interventions.

18 May 2022·Journal of Radiation ResearchQ3 · MEDICINE

Quantifying the dosimetric effects of neck contour changes and setup errors on the spinal cord in patients with nasopharyngeal carcinoma: establishing a rapid estimation method

Q3 · MEDICINE

ArticleOA

Author: Chang, Yuanzhi ; Xie, Qiuying ; Teng, Jianjian ; Li, Yinghui ; Liu, Zhibin ; Shi, Jinping ; Zhang, Liwen ; Wei, Zhanfu ; Chen, Lixin

AbstractThe purpose of this study was to quantify the effect of neck contour changes and setup errors on spinal cord (SC) doses during the treatment of nasopharyngeal carcinoma (NPC) and to establish a rapid dose estimation method. The setup errors and contour changes in 60 cone-beam computed tomography (CBCT) images of 10 NPC patients were analysed in different regions of the neck (C1–C3, C4–C5 and C6–C7). The actual delivered dose to the SC was calculated using the CBCT images, and univariate simulations were performed using the planning CT to evaluate the dose effects of each factor, and an index ${\mathrm{Dmax}}_{\mathrm{displaced}}$ was introduced to estimate the SC dose. Compared with the planned dose, the mean (maximum) Dmax increases in the C1–C3, C4–C5 and C6–C7 regions of the SC were 2.1% (12.3%), 1.8% (8.2%) and 2.5% (9.2%), respectively. The simulation results showed that the effects of setup error in the C1–C3, C4–C5 and C6–C7 regions were 1.5% (9.7%), 0.9% (8.2%) and 1.3% (6.3%), respectively, and the effects of contour change were 0.4% (1.7%), 0.7% (2.5%) and 1.5% (4.9%), respectively. The linear regression model can be used to estimate the dose effect of contour changes (R2 > 0.975) and setup errors (R2 = 0.989). Setup errors may lead to a significant increase in the SC dose in some patients. This study established a rapid dose estimation method, which is of great significance for the daily dose evaluation and the adaptive re-planning trigger of the SC.

01 Dec 2021·Perioperative MedicineQ4 · MEDICINE

Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study

Q4 · MEDICINE

ArticleOA

Author: Tajik, Bashir ; Jiang, Huiqi ; Vanky, Farkas ; Friberg, Örjan ; Svedjeholm, Rolf ; Vidlund, Mårten ; Yang, Yanqi ; Holm, Jonas

AbstractBackgroundPostoperative heart failure (PHF) is the main cause for mortality after cardiac surgery but unbiased evaluation of PHF is difficult. We investigated the utility of postoperative NT-proBNP as an objective marker of PHF after coronary artery bypass surgery (CABG).MethodsProspective study on 382 patients undergoing isolated CABG for acute coronary syndrome. NT-proBNP was measured preoperatively, the first (POD1) and third postoperative morning (POD3). A blinded Endpoints Committee used prespecified criteria for PHF. Use of circulatory support was scrutinized.ResultsAfter adjusting for confounders PHF was associated with 1.46 times higher NT-proBNP on POD1 (p = 0.002), 1.54 times higher on POD3 (p < 0.0001). In severe PHF, NT-proBNP was 2.18 times higher on POD1 (p = 0.001) and 1.81 times higher on POD3 (p = 0.019). Postoperative change of NT-proBNP was independently associated with PHF (OR 5.12, 95% CI 1.86–14.10, p = 0.002). The use of inotropes and ICU resources increased with incremental quartiles of postoperative NT-proBNP.ConclusionsPostoperative NT-proBNP can serve as an objective marker of the severity of postoperative myocardial dysfunction. Due to overlap in individuals, NT-proBNP is useful mainly for comparisons at cohort level. As such, it provides a tool for study purposes when an unbiased assessment of prevention or treatment of PHF is desirable.Trial registrationClinicalTrials.gov Identifier: NCT00489827https://clinicaltrials.gov/ct2/show/NCT00489827?term=glutamics&draw=2&rank=1.

News (Medical) associated with Sun Yat-sen University of Medical Sciences

12 Sep 2023

·www.biospace.com

MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team

WEST CHESTER, Pa.--(BUSINESS WIRE)-- Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage company accelerating the development and global access of life-changing radiopharmaceuticals, announced the appointment of Dr. Jerry Huang, M.D., Ph.D. as the Senior Vice President of Clinical Development. Dr. Huang has over twenty years of global clinical development experience and has had expanding leadership responsibilities in the US, Europe, and Asia Pacific at Taiho Oncology, Novartis, BeiGene and Covance. She guided organizations and teams on clinical strategy, clinical operational practices and process improvement in clinical research and development. Dr. Huang has led multiple oncology clinical studies in advanced solid tumors and orphan oncology indications; completed First-in-Human, Proof-of-Concept, pivotal registration studies, and has experience with multiple health authority interactions (FDA [CDER, CDRH] and EMA). She received her M.D. from Sun Yat-Sen University of Medical Sciences in China, Ph.D. in Biophysics, and an M.S. in Clinical Research Methods from Albert Einstein College of Medicine in the US. Chris Pak, President and CEO of MTTI, said, “MTTI is delighted to welcome Jerry, an experienced biotech executive. Her perspective and track record in oncology and precision medicine development are key complements to our team as we expedite our theranostic pipeline development.” Molecular Targeting Technologies, Inc. (MTTI). MTTI is a privately held, clinical-stage biotech company developing next-generation targeted radiotherapeutics for rare cancers with high unmet medical needs. MTTI is committed to building value by translating innovative radiopharmaceutical assets to improve human health and reduce healthcare costs. MTTI is committing multiple clinical trials to meet that goal in the coming months and years. For more information: View source version on businesswire.com: Contacts Chris Pak, Email: cpak@mtarget.com Source: Molecular Targeting Technologies, Inc. View this news release online at:

Executive Change

100 Deals associated with Sun Yat-sen University of Medical Sciences

100 Translational Medicine associated with Sun Yat-sen University of Medical Sciences

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 16 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sun Yat-sen University of Medical Sciences

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 16 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing